MNG925
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.549
- G2M_CHECKPOINT+0.515
- MYC_TARGETS_V1+0.509
- DNA_REPAIR+0.504
- UNFOLDED_PROTEIN_RESPONSE+0.395
- PEROXISOME+0.384
- MYC_TARGETS_V2+0.367
- MITOTIC_SPINDLE+0.337
- PROTEIN_SECRETION+0.311
- OXIDATIVE_PHOSPHORYLATION+0.309
Top 10 suppressed
- KRAS_SIGNALING_DN-0.349
- ALLOGRAFT_REJECTION-0.311
- TNFA_SIGNALING_VIA_NFKB-0.273
- IL6_JAK_STAT3_SIGNALING-0.263
- INFLAMMATORY_RESPONSE-0.240
- COMPLEMENT-0.206
- KRAS_SIGNALING_UP-0.176
- ESTROGEN_RESPONSE_EARLY-0.160
- ANGIOGENESIS-0.136
- SPERMATOGENESIS-0.111
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-2110 | Med | Medulloblastoma | 0.887 |
| 2 | E0DE33EA-C3DF-478E-9C4D-86E3C7B3A1D9 | — | — | 0.877 |
| 3 | MNG134 | — | — | 0.863 |
| 4 | SRR934941 | — | — | 0.862 |
| 5 | EE4F9349-F750-4471-BFE7-7230784569E1 | — | — | 0.859 |
| 6 | 15824B66-5519-459A-B0C2-6EABAEEC2D8A | — | — | 0.851 |
| 7 | ERR2598070 | fetal | fetal | 0.839 |
| 8 | SRR13311170 | — | — | 0.838 |
| 9 | TCGA-HQ-A5ND-01A-11R-A26T-07 | — | — | 0.836 |
| 10 | TCGA-66-2792-01A-01R-0980-07 | — | cohortSQ2 | 0.834 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 28 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.549 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.515 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.509 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.504 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.395 | Idelalisib | — uncovered |
| PEROXISOME | 0.384 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.367 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.337 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.311 | Remibrutinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.309 | Remibrutinib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.291 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.281 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.262 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.260 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.240 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.213 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.189 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.161 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.149 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.144 | Temsirolimus | — uncovered |